Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response

Conggang Zhang, Zeyu Liu, Eric Bunker, Adrian Ramirez, Schuyler Lee, Yinghua Peng, Aik-Choon Tan, S. Gail Eckhardt, Douglas A. Chapnick, Xuedong Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating advanced renal-cell carcinoma and liver cancer. Despite its well-characterized mechanism of action on several established cancer-related protein kinases, sorafenib causes variable responses among human tumors, although the cause for this variation is unknown. In an unbiased screening of an oncology drug library, we found that sorafenib activates recruitment of the ubiquitin E3 ligase Parkin to damaged mitochondria. We show that sorafenib inhibits the activity of both complex II/III of the electron transport chain and ATP synthase. Dual inhibition of these complexes, but not inhibition of each individual complex, stabilizes the serine-threonine protein kinase PINK1 on the mitochondrial outer membrane and activates Parkin. Unlike the protonophore carbonyl cyanide m-chlorophenylhydrazone, which activates the mitophagy response, sorafenib treatment triggers PINK1/Parkin-dependent cellular apoptosis, which is attenuated upon Bcl-2 overexpression. In summary, our results reveal a new mechanism of action for sorafenib as a mitocan and suggest that high Parkin activity levels could make tumor cells more sensitive to sorafenib's actions, providing one possible explanation why Parkin may be a tumor suppressor gene. These insights could be useful in developing new rationally designed combination therapies with sorafenib.

Original languageEnglish
Pages (from-to)15105-15120
Number of pages16
JournalJournal of Biological Chemistry
Volume292
Issue number36
DOIs
Publication statusPublished - 2017
Externally publishedYes

Fingerprint

Electron Transport
Adenosine Triphosphate
Pharmaceutical Preparations
Tumors
Renal Cell Carcinoma
Electron Transport Complex II
Mitochondrial Degradation
Cells
sorafenib
Neoplasms
Preclinical Drug Evaluations
Mitochondria
Ubiquitin-Protein Ligases
Oncology
Electron Transport Complex III
Protein-Serine-Threonine Kinases
Mitochondrial Membranes
Liver Neoplasms
Tumor Suppressor Genes
Liver

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. / Zhang, Conggang; Liu, Zeyu; Bunker, Eric; Ramirez, Adrian; Lee, Schuyler; Peng, Yinghua; Tan, Aik-Choon; Eckhardt, S. Gail; Chapnick, Douglas A.; Liu, Xuedong.

In: Journal of Biological Chemistry, Vol. 292, No. 36, 2017, p. 15105-15120.

Research output: Contribution to journalArticle

Zhang, Conggang ; Liu, Zeyu ; Bunker, Eric ; Ramirez, Adrian ; Lee, Schuyler ; Peng, Yinghua ; Tan, Aik-Choon ; Eckhardt, S. Gail ; Chapnick, Douglas A. ; Liu, Xuedong. / Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. In: Journal of Biological Chemistry. 2017 ; Vol. 292, No. 36. pp. 15105-15120.
@article{92261da044b745dfb9749348500dab57,
title = "Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response",
abstract = "Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating advanced renal-cell carcinoma and liver cancer. Despite its well-characterized mechanism of action on several established cancer-related protein kinases, sorafenib causes variable responses among human tumors, although the cause for this variation is unknown. In an unbiased screening of an oncology drug library, we found that sorafenib activates recruitment of the ubiquitin E3 ligase Parkin to damaged mitochondria. We show that sorafenib inhibits the activity of both complex II/III of the electron transport chain and ATP synthase. Dual inhibition of these complexes, but not inhibition of each individual complex, stabilizes the serine-threonine protein kinase PINK1 on the mitochondrial outer membrane and activates Parkin. Unlike the protonophore carbonyl cyanide m-chlorophenylhydrazone, which activates the mitophagy response, sorafenib treatment triggers PINK1/Parkin-dependent cellular apoptosis, which is attenuated upon Bcl-2 overexpression. In summary, our results reveal a new mechanism of action for sorafenib as a mitocan and suggest that high Parkin activity levels could make tumor cells more sensitive to sorafenib's actions, providing one possible explanation why Parkin may be a tumor suppressor gene. These insights could be useful in developing new rationally designed combination therapies with sorafenib.",
author = "Conggang Zhang and Zeyu Liu and Eric Bunker and Adrian Ramirez and Schuyler Lee and Yinghua Peng and Aik-Choon Tan and Eckhardt, {S. Gail} and Chapnick, {Douglas A.} and Xuedong Liu",
year = "2017",
doi = "10.1074/jbc.M117.783175",
language = "English",
volume = "292",
pages = "15105--15120",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "36",

}

TY - JOUR

T1 - Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response

AU - Zhang, Conggang

AU - Liu, Zeyu

AU - Bunker, Eric

AU - Ramirez, Adrian

AU - Lee, Schuyler

AU - Peng, Yinghua

AU - Tan, Aik-Choon

AU - Eckhardt, S. Gail

AU - Chapnick, Douglas A.

AU - Liu, Xuedong

PY - 2017

Y1 - 2017

N2 - Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating advanced renal-cell carcinoma and liver cancer. Despite its well-characterized mechanism of action on several established cancer-related protein kinases, sorafenib causes variable responses among human tumors, although the cause for this variation is unknown. In an unbiased screening of an oncology drug library, we found that sorafenib activates recruitment of the ubiquitin E3 ligase Parkin to damaged mitochondria. We show that sorafenib inhibits the activity of both complex II/III of the electron transport chain and ATP synthase. Dual inhibition of these complexes, but not inhibition of each individual complex, stabilizes the serine-threonine protein kinase PINK1 on the mitochondrial outer membrane and activates Parkin. Unlike the protonophore carbonyl cyanide m-chlorophenylhydrazone, which activates the mitophagy response, sorafenib treatment triggers PINK1/Parkin-dependent cellular apoptosis, which is attenuated upon Bcl-2 overexpression. In summary, our results reveal a new mechanism of action for sorafenib as a mitocan and suggest that high Parkin activity levels could make tumor cells more sensitive to sorafenib's actions, providing one possible explanation why Parkin may be a tumor suppressor gene. These insights could be useful in developing new rationally designed combination therapies with sorafenib.

AB - Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating advanced renal-cell carcinoma and liver cancer. Despite its well-characterized mechanism of action on several established cancer-related protein kinases, sorafenib causes variable responses among human tumors, although the cause for this variation is unknown. In an unbiased screening of an oncology drug library, we found that sorafenib activates recruitment of the ubiquitin E3 ligase Parkin to damaged mitochondria. We show that sorafenib inhibits the activity of both complex II/III of the electron transport chain and ATP synthase. Dual inhibition of these complexes, but not inhibition of each individual complex, stabilizes the serine-threonine protein kinase PINK1 on the mitochondrial outer membrane and activates Parkin. Unlike the protonophore carbonyl cyanide m-chlorophenylhydrazone, which activates the mitophagy response, sorafenib treatment triggers PINK1/Parkin-dependent cellular apoptosis, which is attenuated upon Bcl-2 overexpression. In summary, our results reveal a new mechanism of action for sorafenib as a mitocan and suggest that high Parkin activity levels could make tumor cells more sensitive to sorafenib's actions, providing one possible explanation why Parkin may be a tumor suppressor gene. These insights could be useful in developing new rationally designed combination therapies with sorafenib.

UR - http://www.scopus.com/inward/record.url?scp=85029222034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029222034&partnerID=8YFLogxK

U2 - 10.1074/jbc.M117.783175

DO - 10.1074/jbc.M117.783175

M3 - Article

C2 - 28673964

AN - SCOPUS:85029222034

VL - 292

SP - 15105

EP - 15120

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 36

ER -